Arch Therapeutics, Inc.

ARTHCIK 0001537561 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Mar 1, 2024. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0014

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 23, 2025no items parsed Feb 7, 2025no items parsed Jan 23, 2025no items parsed Nov 7, 2024no items parsed Nov 4, 2024no items parsed

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Arch Therapeutics, Inc.

Name	Roles	Filings
Abrams Michael S	Officer	1
Fish Guy L.	Director	1
Hicks Laurence	Director	1
Norchi Terrence W	OfficerDirector	1
Yrigoyen Dan	Officer	1

Showing 1-5 of 5

Per pagePage 1 of 1

All filings

5 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Sep 8, 2023	Hicks Laurence Director	PPurchase	10,292	$0.275	$2,830
Sep 8, 2023	Norchi Terrence W PRESIDENT AND CHIEF EXECUTIVE · Director	PPurchase	6,862	$0.275	$1,887
Sep 8, 2023	Abrams Michael S CHIEF FINANCIAL OFFICER	PPurchase	10,292	$0.275	$2,830
Jun 9, 2022	Yrigoyen Dan VICE PRESIDENT, SALES	Holdings only	-	-	-
Jan 4, 2022	Fish Guy L. Director	Holdings only	-	-	-